|
|
|
| Cheminor Drugs Q2 sales down by 2.42% |
Cheminor Drugs Ltd has informed BSE:
1.Total sales are at Rs.556.2 million in the second quarter of FY2001 against Rs.570 million during the same period of 1999-2000 a marginal decline of 2.42%
2.Ibuprofen fanitidine, Naproxen, Dextromethorphan, Doxazocin and Sertraline HCL account for 65% of the total sales.
3.US and European markets contributes 58% to the total sales
4.Sales to the US markets increased by 19%
5.Formulation sales at Rs.21.66 million
|
| Bausch & Lomb Q2 results on October 25, 2000 |
| A meeting of the Board of Directors of Bausch & Lomb India Ltd has been convened on October 25, 2000 to consider, inter-alia quarterly Un-audited Financial Results for the period ended on 30th September, 2000.
|
| Sierra Optima Q2 net profit up 113.15% |
| Sierra Optima Ltd has posted a net profit of Rs 26.90 million for the quarter ended September 30, 2000 as compared to Rs 12.62 million in the same period last year. Net sales for the quarter ended September 30, 2000 are at Rs 90.18 million as compared to Rs 40.30 million in SQ 99. Other income has increased from Rs 0.14 million in SQ 99 to Rs 1.45 million in the quarter ended September 30, 2000.
|
| Elgitread Q2 net profit down by 21.32% |
| Elgitread (India) Ltd has posted a net profit of Rs 52.81 million for the quarter eneded September 30, 2000 as compared to Rs 67.12 million in the same period last year. Net sales have decreased from Rs 239.75 million in SQ 99 to Rs 230.83 million in the quarter ended September 30, 2000. Other income has increased from Rs 12.19 million in SQ 99 to Rs 20.34 million in the quarter ended September 30, 2000.
|
| Bayer Diagnostics Q3 net up by 95.16% |
| Bayer Diagnostics Ltd has posted a net profit of Rs 12.38 million for the quarter ended September 30, 2000 as compared to Rs 6.53 million in the same period last year. Net sales for the quarter ended September 30, 2000 are at Rs 149.81 million as against Rs 108.85 million in SQ 99. Other income for the quarter ended September 30, 2000 is at Rs 0.18 million as compared to Rs 0.78 million in SQ 99.
|
| Dr Reddy's Q2 sales grow by 46% |
The Board of Directors of Dr.Reddys Laboratories Limited has informed BSE about the Performance review for Second Quarter i.e. (July2000-September2000)
1.Sales for the second quarter grew at 46% from Rs.1135.70 million in Q2 of F.Y.2000 to Rs.1654.57 million.
2.Contribution from Finished Dosages business was 68% for the quarter.
3.The contribution of finished dosages India business segment was 52% to the total turnover of the quarter
4.Bulk actives business contributed 30% and the balance from diagnostics
5. Turnover for H1 of FY 2001 is at Rs.3039.69 millions, a growth of 25%
The Board of Directors of Dr Reddy's Laboratories Ltd will meet on October 30,2000 to take on record the un-audited results for the first half of the current financial year.
|
| Castrol Q3 net down by 40.22% |
Castrol India Ltd has posted a net profit of Rs 281.40 million for the quarter ended September 30, 2000 as compared to Rs 470.80 million in the same period last year. Net sales for the quarter ended September 30, 2000 are up by 3.61% at Rs 2900.70 million as compared to Rs 2799.70 million in SQ 99. Other income for the quarter ended September 30, 2000 is at Rs 23.50 million as compared to Rs 39.80 million in the same period last year.
The Company has stopped commercial production at its Wadala Plant with effect from 1st July 2000 following the acceptance of the Voluntary Retirement Scheme by all the plant employees. However, the premises will continue to be used to house the Companys R&D centre and certain corporate functions.
Mr R Gopalkrishnan Executive Director Tata Sons Ltd and former Vice Chairman Hindustan Lever Ltd has joined the Board of Directors as a non-executive independent Director of the company wef October 17, 2000.
|
| Videocon International Q2 results on October 30, 2000 |
| A meeting of the Board of Directors of Videocon International Ltd has been convened on October 30, 2000 to consider the unaudited financial results for the quarter ended September 30, 2000. |
| United Phosphorus Q2 results on October 31, 2000 |
| A meeting of the Board of Directors of United Phosphorus Ltd Ltd has been convened on October 31, 2000 to consider the unaudited financial results for the quarter ended September 30, 2000. |
Housing Development Finance Corporation Ltd has posted a net profit of Rs 1163.6 million for the quarter ended September 30, 2000 as compared to Rs 971/- million in the same period last year. Interest earned & Operating Income for the quarter ended September 30, 2000 is at Rs 5861.80 million as compared to Rs 4838.80 million in SQ 99. Other income for the quarter ended September 30, 2000 is at Rs 37.50 million as compared to Rs 6.30 million in SQ 99.
During the year, the Corporation invested Rs 500.10 million and Rs 99.90 million in Home Trust Housing Finance Company Ltd and GRUH Finance Ltd respectively, consequent to which these companies have become subsidiaries of the Corporation. |
| Smithkline Beecham Pharma Q3 net up by 27.58% |
Smithkline Beecham Pharmaceuticals (India) Ltd has posted a net profit of Rs 72.91 million for the quarter ended September 30, 2000 as compared to Rs 57.15 million in the same period last year. Net sales for SQ 2000 are at Rs 762.18 million as compared to Rs 760.14 million in the same period last year. Other income has increased from Rs 19.68 million in the quarter ended September 30, 99 to Rs 22.60 million in the quarter ended September 30, 2000.
During the quarter the company launched Tritanrix-HB the first vaccine in the world to combine Hepatitis and DTPw vaccines thereby offering protection against four major diseases. This new vaccine offers significant advantages in terms of value, convenience, and improved compliance to both doctor and consumer and demonstrates again SB's global leadership in vaccine technology. The response to this new breakthrough has been tremendous and over the next few months the company expects sales and market share to grow significantly. New value added products like Fefol-Z are also perfoming in line with expectations.As a result of this initiatives,and increasingly strong perfomances from existing brands such as Augmentin and Iodex, the company expects the declining sales trend to be reversed in coming months.
At the same time the company has implemented a numder of major cost reduction initiatives which have contributed to improved profitability .As a result of buying efficiencies raw material costs have been contained and overall expenses during the quarter were lower than for the same period last year in spite of inflation and the investment in new products.The company is also reaping the benefits of world class ERP systems implemented during the last 18 months which have contributed to significant reductions in inventory holding and improvements in overall working capital management. |
| Colgate-Palmolive Q2 results on October 24, 2000 |
| A meeting of the Board of Directors of Colgate-Palmolive India Ltd is scheduled to be held on October 24, 2000 to take on record the unaudited financial results for the quarter ended September 30, 2000. |
| Coates to consider transfer of adhesive business |
A meeting of the Board of Directors of Coates of India Ltd has been convened on October 24, 2000 to consider
1. Unaudited Financial results for the quarter ended September 30, 2000
2. Transfer of Adhesive business to Bostik India Private Ltd on a slump sale basis
3. Fixing of record date for EGM of the members to consider transfer of the company's adhesive business to Bostik India Private Ltd. |
| BHEL Q2 results on October 30, 2000 |
| A meeting of the Board of Directors of Bharat Heavy Electricals Ltd has been convened on October 30, 2000 to consider the unaudited financial results for the quarter ended September 30, 2000. |
| Precision Wires shareholders approve amalgamation of Atlas Wires |
| Shareholders of Precision Wires India Ltd have approved the proposal of amalgamation of Atlas Wires Ltd. with the company. The Directors had already approved the amalgamation of Atlas Wires India (AWIL) Ltd with the company with effect from April 1, 2000. |
| HPCL Q2 results on October 30, 2000 |
| A meeting of the Board of Directors of Hindustan Petroleum Corporation Ltd has been convened on October 30, 2000 to consider the unaudited financial results for the second quarter ended September 30, 2000. |
| Tata Elxsi Q2 results on October 24, 2000 |
| A meeting of the Board of Directors of Tata Elxsi Ltd has been convened on October 24, 2000 to consider among other matters the unaudited financial results for quarter ended September 30, 2000. |
| Hi-Tech Gears Q2 net profit up by 4.42%, declares 10% interim dividend |
Hi-Tech Gears Ltd has posted a net profit of Rs 9.94 million for the quarter ended September 30, 2000 as compared to Rs 9.52 million in the corresponding quarter of the same period last year. Net sales for the quarter ended September 30, 2000 are at Rs 198.78 million as compared to Rs 158.55 million in the same period last year. Other income for the quarter ended September 30, 2000 is at Rs 1.50 million as compared to Rs 0.67 million in SQ 99.
The Board of Directors of the Company has recommended a payment of interim dividend @10% to the Shareholders. Further the Board of Directors has fixed 30th Nov.2000 as the Record date for determining the list of Shareholders entitled for the interim dividend.
|
Money
Rapid Information on Stocks & Corporates
Tell us what you think of this report
|
